# Pamela Conley

> Pamela Conley, Ph.D., is the cofounder, chief scientific officer and founding CEO of Nuvig Therapeutics. Her career includes research leadership at Portola Pharmaceuticals, Millennium Pharmaceuticals and COR Therapeutics, alongside board service at Cellphire. She studied biochemistry at the University of Texas at Austin and UC Berkeley and completed postdoctoral research at Stanford.

- **Role:** Cofounder & Chief Scientific Officer at Nuvig Therapeutics
- **Organizations:** Nuvig Therapeutics, Cellphire, Portola Pharmaceuticals, Millennium Pharmaceuticals, COR Therapeutics, iPierian
- **Education:** B.A. in Biochemistry, University of Texas at Austin, Ph.D. in Biochemistry, University of California, Berkeley, Postdoctoral research; Howard Hughes Institute and Carnegie Institution, Stanford University
- **Known for:** Cofounded Nuvig and led the company as founding CEO., Led multidisciplinary research functions at Portola Pharmaceuticals., Coauthored scientific publications and holds issued patents.

## Career timeline

- **1991-2001** — Scientist and project leader at COR Therapeutics.
- **2001-2003** — Biology leadership at Millennium Pharmaceuticals.
- **2003-2012** — Vice President of Research Biology at Portola Pharmaceuticals.
- **2012** — Vice President of Research at iPierian.
- **2013-2020** — Returned to Portola, serving as Vice President of Biology and then Senior Vice President of Research.
- **2021** — Cofounded Nuvig Therapeutics.
- **2022** — Nuvig launched publicly with a $47 million Series A; Conley was founding CEO.
- **2023** — Became Nuvig chief scientific officer when Julie Anne Smith was appointed CEO.
- **2024** — Nuvig announced a $161 million Series B.
- **2025** — Welcomed David Woodhouse as Nuvig CEO and James Mackay as independent board chair.

## Achievements

- Cofounded Nuvig and led the company as founding CEO.
- Led multidisciplinary research functions at Portola Pharmaceuticals.
- Coauthored scientific publications and holds issued patents.
- Serves on Cellphire’s board of directors.

## Latest updates

- **2026-05** — Publicly described Nuvig’s continuing patent-advisory relationship with Sabrina Poulos and the Antheros team.
- **2025-09** — Commented on the appointments of David Woodhouse as CEO and James Mackay as independent chair.
- **2024-12** — Nuvig announced its $161 million Series B financing.

## Links

- Website: https://nuvigtx.com/team/
- LinkedIn: https://www.linkedin.com/in/pamela-conley-9b7367

---

Profile page: https://yespress.io/pamela-conley
Published by YesPress — https://yespress.io
Last updated: 2026-10-11